XML 32 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE (Tables)
12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholsesaler Service Fees and Prompt Pay Discounts for the years ended December 31, 2019, 2018 and 2017 (in thousands):
 
Returns Allowances
 
Prompt Payment Discounts
 
Wholesaler Service Fees
 
Volume Rebates and Chargebacks
 
Total
Balance at December 31, 2016
$
1,346

 
$
595

 
$
735

 
$
1,124

 
$
3,800

   Provision
716

 
5,806

 
4,403

 
4,656

 
15,581

   Payments/Adjustments
(1,241
)
 
(5,744
)
 
(4,299
)
 
(5,084
)
 
(16,368
)
Balance at December 31, 2017
821

 
657

 
839

 
696

 
3,013

   Provision
680

 
6,802

 
5,194

 
6,645

 
19,321

   Payments/Adjustments
(1,157
)
 
(6,680
)
 
(4,866
)
 
(6,331
)
 
(19,034
)
Balance at December 31, 2018
344

 
779

 
1,167

 
1,010

 
3,300

   Provision
783

 
8,426

 
6,267

 
11,475

 
26,951

   Payments/Adjustments
(587
)
 
(8,243
)
 
(5,948
)
 
(10,669
)
 
(25,447
)
Balance at December 31, 2019
$
540

 
$
962

 
$
1,486

 
$
1,816

 
$
4,804


Disaggregation of Revenue
The following table represents disaggregated net product sales in the periods presented as follows (in thousands):
 
Year Ended December 31,
 
2019
 
2018
 
2017
 Net product sales:
 
 
 
 
 
      EXPAREL / bupivacaine liposome injectable suspension
$
411,030

 
$
332,427

 
$
283,252

      iovera°
7,896

 

 

      DepoCyt(e)

 

 
1,090

 Total net product sales
$
418,926

 
$
332,427

 
$
284,342